Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target
$NMTC
Medical/Dental Instruments
Health Care
Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $1.45 | Buy | Ladenburg Thalmann |
| 3/29/2022 | $6.00 → $2.00 | Buy → Hold | Craig Hallum |
| 12/3/2021 | $5.75 | Buy | Alliance Global Partners |
| 11/15/2021 | $6.00 | Buy | Craig-Hallum |
Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f
Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024. First Quarter Financial Highlights Product revenue increased 235% to $3.3 million in the first quarter of fiscal year 2025, compared to $1.0 million in the first quarter of fiscal
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at
EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs. Mr. Wilhelmy joins NeuroOne from HLT Medical, a subsidiary of the Bracco Group, where he was the Vice President Quality Assurance. Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "Chad's appointment further strengthens our executive leadership team and deepens our capabilities as we build the pla
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45
Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously
Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)